StockDiagnostics.com monitors a public company's Operational-cashflow Per Share ("OPS") and assigns it an "OPS Ranking". OPS Rankings measure the long term risk associated with a company's ability to remain in business. They were discovered from in-depth research conducted by StockDiagnostics.com on operational cash flow. These studies revealed that a company's "OPS" (Operational- cashflow Per Share) logically falls into a mathematical sequence that ranks it into one of eight distinctive "risk" categories. Each of the categories is based on a company's operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months.

The OPS Ranking is based on a computer-generated, precise and objective calculation of a company's quarterly cash flow consistency and its annualized cash flow at the end of its most recent quarter. There are eight possible OPS Rankings scaled one (1) through eight (8), with an OPS Ranking of one (1), being the highest ranking and an eight (8), being the lowest. Historical research has shown that companies with the highest OPS Ranking (1) have the least risk for going out of business and companies with the lowest OPS Ranking (8) have the most risk.

About OPS Ranking Upgrades and Downgrades

OPS Rankings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. OPS Ranking upgrades and downgrades may predict changes in the momentum of a company's stock price and its inherent or presumed financial health. All OPS Ranking downgrades, even a downgrade from the highest OPS Ranking of "1" to the second highest OPS Ranking of "2" should be treated with equal caution. Similarly, all OPS Ranking upgrades should be considered as equally positive. Even an upgrade from the lowest OPS Ranking of "8" to the second lowest OPS Ranking of "7" can be treated with guarded optimism. For statistical research on OPS Rankings click here.

About StockDiagnostics.com

StockDiagnostics.com actively monitors over 10,000 public companies for financial statement anomalies. The company has spent 6 years and approximately $20 million on developing a suite of proprietary software products designed to reveal the logical relationships between financial statement anomalies and stock price performance. StockDiagnostics.com has been featured in Barron's, Money Magazine, Investors Business Daily, Inc. Magazine and various other leading financial publications.